Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. - Wikidata - wikimedia - TriplyDB

Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression.

Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression.

http://www.wikidata.org/entity/Q34508765

about

sameAs

The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic Unexplained Painful Physical Symptoms in Patients with Major Depressive Disorder: Prevalence, Pathophysiology and Management Emerging drugs for the treatment of anxiety Emerging targets for antidepressant therapies A new paradigm for depression in new mothers: the central role of inflammation and how breastfeeding and anti-inflammatory treatments protect maternal mental health Novel targets for antidepressant therapies A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults The clinical implications of mouse models of enhanced anxiety.Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer cell innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial.Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists.Future prospects in depression research Advances in the Management of Treatment-Resistant Depression The neurokinin-1 receptor antagonist aprepitant in co-morbid alcohol dependence and posttraumatic stress disorder: a human experimental study.Cortical nNOS neurons co-express the NK1 receptor and are depolarized by Substance P in multiple mammalian species.Altered amygdala activation during face processing in Iraqi and Afghanistani war veterans Substance P excites GABAergic neurons in the mouse central amygdala through neurokinin 1 receptor activation.Depression and posttraumatic stress disorder among women with vulvodynia: evidence from the population-based woman to woman health study NK1 receptor antagonists under investigation for the treatment of affective disorders.Emerging treatments for depression.Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition?The effects of yohimbine and amphetamine on fear expression and extinction in rats.Increased neurokinin-1 receptor availability in the amygdala in social anxiety disorder: a positron emission tomography study with [11C]GR205171.Reducing adsorption to improve recovery and in vivo detection of neuropeptides by microdialysis with LC-MS.Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ.Classical neurotransmitters and neuropeptides involved in major depression: a review.Psychoneuroimmunologic factors in inflammatory bowel disease.An intricate relationship between pain and depression: clinical correlates, coactivation factors and therapeutic targets.Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia.Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies.Physiologic changes associated with violence and abuse exposure: an examination of related medical conditions.The association between substance P and white matter integrity in medication-naive patients with major depressive disorder.Functional effects of polymorphisms on glucocorticoid receptor modulation of human anxiogenic substance-P gene promoter activity in primary amygdala neurones Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study.A Chitosan-Based Liposome Formulation Enhances the In Vitro Wound Healing Efficacy of Substance P Neuropeptide.Overlapping expression of serotonin transporters and neurokinin-1 receptors in posttraumatic stress disorder: a multi-tracer PET study.Plasma and cerebrospinal fluid substance P in post-stroke patients with depression.Association between amygdala neurokinin-1 receptor availability and anxiety-related personality traits

P2860

Q24658278-787B5410-74DF-496C-9805-94CB02B68F55 Q24658278-D05ABF90-4E96-41FD-ACEE-7AEC9800D712 Q26751458-63731ABB-AC98-401A-A4E1-A4718CA76D26 Q26751458-E2345F53-7F7C-4E43-A483-0213C36597FF Q28083141-14EF054C-2B52-48B9-BEFF-FD56868CE580 Q28083141-1F1CCE52-F669-4422-9AB5-6B74046F48D9 Q28247614-613C268C-D346-4AE5-A799-AF70DBA075BE Q28247614-9D757165-4FEB-4DB3-9883-EC649C4BF337 Q28395601-5E3434F4-5965-49C3-A7B7-EAFEFE7BC92F Q28395601-ACAF00FE-22CC-4EDA-83A2-D67957CA3B34 Q28648254-A4859F4F-6542-47A0-ADAA-ACE8F93F6A9C Q28648254-FE75BE50-C7AF-43EB-80DE-E448BADB442F Q28740565-B90C2946-0A06-4F79-999B-AC96BFFA13F1 Q28740565-FC80C403-7A1D-45C7-AD4D-C826756E21D5 Q30474232-4D0A5F24-4447-4226-913E-4E8F01B5848C Q30474232-F7DC0AF1-8E34-4A17-9AC8-C8A77DE7564E Q30479172-93708221-86D2-4FD0-A6F0-5FE66B81C2E8 Q30479172-E47CD4DD-31CC-4FC1-A4B1-462264D0393F Q33752757-3826A473-2EB3-4BEB-A81D-81AB848C03A9 Q34157073-6CDB9D7F-AF6B-428A-9DF8-D3D430DCC747 Q34157073-EAFCB33F-46F2-4ACD-8074-C74F47133ECB Q34376340-5D3528C3-440B-46C6-BC2D-C2710ADED941 Q35236701-6901F954-9A6F-4210-90DC-0BD0982BCE03 Q35580600-CFD8E09C-DAD9-4A48-AF93-6376685BB305 Q35881528-13DA9610-02E9-4B46-BE78-AC550506A18B Q35881528-1D76C35D-40D9-4A57-A717-666A18A3E212 Q36009120-2201FC0D-4CA3-4056-8701-652B731854F0 Q36009120-DB927AA5-66A2-4790-B71C-3FE27EDA80CC Q36061759-77D0A0AF-3FB9-4D6F-BC10-3152BFFC60D0 Q36061759-CDCAEB59-E9C8-4FF5-8903-E02780C41A93 Q36205025-5E88D2E1-804F-47E2-852C-70F7E5118A69 Q36205025-A3F83278-1ED4-450F-9861-B8229A6D6CC6 Q36234718-1130CC49-2456-46E5-A7B0-51DA4F4E57A5 Q36234718-EDB3FD3A-ABFA-45BC-A8BE-F34658C2331B Q36458364-AF98CCA3-30C6-4CC2-AD74-6E84F97A7E0C Q36655168-8578B10C-1162-49FA-BA84-5B2C7686F27C Q37183514-3FDD92FC-7439-4A6C-B356-CBDFF9B9B723 Q37183514-558A3C3B-E60B-40F9-824C-101F570FE4A2 Q37217230-0835EE61-6535-4393-AB21-6DA17BE79D1E Q37217230-493C1589-1B0D-47E8-AED2-9001EE95F1B0

P2860

Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression.

http://www.wikidata.org/entity/Q34508765

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Elevated cerebrospinal fluid s ...... disorder and major depression.

@ast

Elevated cerebrospinal fluid s ...... disorder and major depression.

@en

Elevated cerebrospinal fluid s ...... disorder and major depression.

@nl

type

label

Elevated cerebrospinal fluid s ...... disorder and major depression.

@ast

Elevated cerebrospinal fluid s ...... disorder and major depression.

@en

Elevated cerebrospinal fluid s ...... disorder and major depression.

@nl

altLabel

Elevated Cerebrospinal Fluid S ...... Disorder and Major Depression

@en

Elevated Cerebrospinal Fluid S ...... Disorder and Major Depression

@nl

prefLabel

Elevated cerebrospinal fluid s ...... disorder and major depression.

@ast

Elevated cerebrospinal fluid s ...... disorder and major depression.

@en

Elevated cerebrospinal fluid s ...... disorder and major depression.

@nl

P1433

Q34508765-D20F70CC-277F-49DA-915C-E186BDC6DB1D

P1476

Q34508765-1377730F-20B1-4801-BCBD-0CC71044317C

Q34508765-97799368-2B8A-4DFE-A45A-FF22257FE7D2

P2093

Q34508765-09D5C287-D1CC-4395-9B5F-8FBA4B0C03B9

Q34508765-15A45ED5-DED6-4A55-991C-11778FFA9B13

Q34508765-2418BF72-902C-4C05-A8F4-DB2E00A74F51

Q34508765-289E24F5-C441-403F-A3FC-192C10B149D9

Q34508765-2C216124-DA63-4F80-8E9B-EA9AE53E502D

Q34508765-399D7453-BA54-4D17-BE4C-2C482E910430

Q34508765-75B1A282-A23D-4F6C-9DA7-B0DCCD245AED

Q34508765-8345E601-44BD-4558-867A-D579FD38218E

Q34508765-894AF17E-B0D0-47B7-B3DF-0110A462B589

Q34508765-A8967580-071C-4793-BEF1-A2885096F026

P304

Q34508765-235958CD-6B4A-410E-A64F-C98B951D15CA

Q34508765-DB46BDEF-F614-4EED-AFCB-0C965F54220E

P31

Q34508765-DB34B0F8-F929-4C3A-8C39-A136C9D52F64

P356

Q34508765-BC72F3F5-A4C1-40A1-BDF9-9108C51137E3

Q34508765-E06E4815-2AEC-4E16-BB6C-A137A29B62BE

P407

Q34508765-622E5A36-07E8-44D9-9944-118D6E6AC609

P433

Q34508765-59F9761D-1404-4823-AED9-2333E9A7E16B

P478

Q34508765-81282420-0C7F-4B78-8ABD-574CE674F4CC

P577

Q34508765-06B9A047-C015-4FC6-9BF1-2D2E45205018

P5875

Q34508765-94CB2FFE-297F-4B7F-B7D1-F5AE5769ADD8

P698

Q34508765-1579D6F8-31CD-4711-8FD5-EA369EFEC2AD

P921

Q34508765-1F6F9B00-39D5-4C6E-81E6-701551813EE3

Q34508765-96B1892E-8DF6-44A7-8C33-F4245382BB0E

P356

AJP.2006.163.4.637

APPI.AJP.163.4.637

P1433

American Journal of Psychiatry

P1476

Elevated Cerebrospinal Fluid S ...... Disorder and Major Depression

@en

Elevated cerebrospinal fluid s ...... disorder and major depression.

@en

P2093

Becky Kinkead

http://www.w3.org/2001/XMLSchema#string

Charles B Nemeroff

http://www.w3.org/2001/XMLSchema#string

Dewleen G Baker

http://www.w3.org/2001/XMLSchema#string

Gerard Sanacora

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Strawn

http://www.w3.org/2001/XMLSchema#string

Lawrence H Price

http://www.w3.org/2001/XMLSchema#string

Linda L Carpenter

http://www.w3.org/2001/XMLSchema#string

Michael J Owens

http://www.w3.org/2001/XMLSchema#string

Nosakhare N Ekhator

http://www.w3.org/2001/XMLSchema#string

Paul S Horn

http://www.w3.org/2001/XMLSchema#string

P304

637

http://www.w3.org/2001/XMLSchema#string

637-643

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1176/AJP.2006.163.4.637

http://www.w3.org/2001/XMLSchema#string

10.1176/APPI.AJP.163.4.637

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

163

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7195461

http://www.w3.org/2001/XMLSchema#string

P698

16585438

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid